IRVINE, Calif.—Allergan (NYSE: AGN) had a 22.1 percent increase (up 17.4 percent at constant currency rates) in its sales of eyecare pharmaceuticals in this year’s first quarter, to $492.2 million.

The company’s total product sales for the period reached $1,061 million, up 23 percent (up 18.5 percent at constant currency rates).
Allergan’s net income in Q1 was $111 million, up from $44 million in the first quarter of 2007.

Looking ahead, the company is forecasting total product net sales of between $1,130 million and $1,160 million for this year’s second quarter.